학술논문
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Document Type
Article
Author
Motzer, Robert J ; Rini, Brian I; McDermott, David F; Arén Frontera, Osvaldo; Hammers, Hans J; Carducci, Michael A; Salman, Pamela; Escudier, Bernard; Beuselinck, Benoit; Amin, Asim; Porta, Camillo; George, Saby; Neiman, Victoria; Bracarda, Sergio; Tykodi, Scott S; Barthélémy, Philippe; Leibowitz-Amit, Raya; Plimack, Elizabeth R; Oosting, Sjoukje F; Redman, Bruce; Melichar, Bohuslav; Powles, Thomas; Nathan, Paul; Oudard, Stéphane; Pook, David; Choueiri, Toni K; Donskov, Frede; Grimm, Marc-Oliver; Gurney, Howard; Heng, Daniel Y C; Kollmannsberger, Christian K; Harrison, Michael R; Tomita, Yoshihiko; Duran, Ignacio; Grünwald, Viktor; McHenry, M Brent; Mekan, Sabeen; Tannir, Nizar M
Source
In The Lancet Oncology October 2019 20(10):1370-1385
Subject
Language
ISSN
1470-2045